Belimumab for systemic lupus erythematosus

The Lancet

Volumn 377, Issue 9783, 2011, Pages 2080-

  Chiche, Laurent ^a   Jourde, Noémie ^a   Mancini, Julien ^a  

^a HÔPITAL DE LA CONCEPTION   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BELIMUMAB; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PLACEBO; PREDNISONE; MONOCLONAL ANTIBODY;

HUMAN; LETTER; PRIORITY JOURNAL; SYSTEMIC LUPUS ERYTHEMATOSUS; TREATMENT FAILURE; NOTE;

ANTIBODIES, MONOCLONAL; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 79959327872     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(11)60912-4     Document Type: Letter

References (5)

1. SV Navarra, RM Guzmán, AE Gallacher for the BLISS-52 Study Group Efficacy and safety of belimumab in patients with active systemic lupus erythematosus: a randomised, placebo-controlled, phase 3 trial Lancet 377 2011 721 731
2. RA Furie, MA Petri, DJ Wallace et al. Novel evidence-based systemic lupus erythematosus responder index Arthritis Rheum 61 2009 1143 1151
3. GB Appel, G Contreras, MA Dooley for the Aspreva Lupus Management Study Group Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis J Am Soc Nephrol 20 2009 1103 1112
4. JT Merrill, CM Neuwelt, DJ Wallace et al. Efficacy and safety of rituximab in moderately-to-severely active systemic lupus erythematosus: the randomized, double-blind, phase II/III systemic lupus erythematosus evaluation of rituximab trial Arthritis Rheum 62 2010 222 233
5. American College of Rheumatology Ad Hoc Committee on Systemic Lupus Erythematosus Response Criteria The American College of Rheumatology response criteria for systemic lupus erythematosus clinical trials: measures of overall disease activity Arthritis Rheum 50 2004 3418 3426